(Q30390955)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23924803%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

Immunogenicity of mAbs in non-human primates during nonclinical safety assessment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23924803%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23924803%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Peter J K van Meer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23924803%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Marlous Kooijman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23924803%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Vera Brinks

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23924803%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Christine C Gispen-de Wied

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23924803%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Ellen H M Moors

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23924803%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Huub Schellekens

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23924803%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

6 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23924803%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

published in

Monoclonal Antibodies

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23924803%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23924803%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23924803%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

810-816

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23924803%20AND%20SRC:MED&resulttype=core&format=json

Immunogenicity assessment in non-clinical studies

7 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

Immunogenicity of therapeutic proteins: the use of animal models

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

Safety evaluation of biological drugs: what are toxicology studies in primates telling us?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

Have we overestimated the benefit of human(ized) antibodies?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

Preclinical development of monoclonal antibodies: considerations for the use of non-human primates

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

Immunotoxicity of monoclonal antibodies

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

Dealing with immunogenicity of biologicals: assessment and clinical relevance

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

Antidrug antibody assay validation: industry survey results

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

Immunogenicity of biopharmaceuticals

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

De-immunization of therapeutic proteins by T-cell epitope modification.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

Factors influencing the immunogenicity of therapeutic proteins

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

Immunogenicity of engineered antibodies

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

Immunogenicity of therapeutic proteins: clinical implications and future prospects

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

Immunogenicity of biopharmaceuticals in laboratory animals

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

Antibody humanization: a case of the 'Emperor's new clothes'?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3851233

Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein.

20 June 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.25234

Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.25234

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.25234

Taking immunogenicity assessment of therapeutic proteins to the next level.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.25234

A comparison of human and macaque (Macaca mulatta) immunoglobulin germline V regions and its implications for antibody engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.25234

The immunogenicity of therapeutic proteins

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23924803

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Strategies and assays for the assessment of unwanted immunogenicity

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23924803

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4161/MABS.25234

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23924803%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23924803%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

PubMed publication ID

23924803

1 reference